Seeking Alpha

Actavis price target set at $250 following Forest deal

  • Following a bit of skepticism from BMO yesterday about its $25B acquisition of Forest Labs (FRX), Actavis (ACT) gets some sell-side love as several firms give the latter a price target of $250, well above its close of $201.47.
  • Goldman Sachs upgrades Actavis to Buy, saying the company is rapidly transforming into one of the fastest-growing names in their coverage.
  • And while Buckingham and Barcap set price targets of $250, their upside cases are $274 and $275 respectively.
  • Actavis shares are +2% to $205.52 premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)